Eyluxvi
Aflibercept biosimilar developed by Alteogen, development code ALT-L9. Reference product Eylea.
Brands by market: Eyluxvi (EU) · Commercial partner or holder: Biolitec pharma (EU holder) · Company profile
FDANot listed
EMASep 2025authorised
MHRANot listed
PMDANot listed
HCNot listed
CDSCONot listed
EDENot listed
Approved or registered in 1 of 7 markets
Connections
About Eyluxvi
Eyluxvi is the aflibercept developed by Alteogen of Korea, approved in Europe in September 2025 with Biolitec as the licence holder. Alteogen is better known for its technology for turning infusions into injections, and this is its first biosimilar approval in Europe.
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union · Eyluxvi
European Medicines Agency and European CommissionApprovedBrand
Eyluxvi
Holder or applicant
Biolitec pharma Limited Zweigniederlassung Jena
Pathway
Centralised (Article 10(4))
Approved
Sep 2025
Application or permission
EMEA/H/C/006282
Presentations
see SmPC
Source
S017 (EMA) · checked Sep 2026
MHRA
United Kingdom
Not listed by MHRA.
PMDA
Japan
Not listed by PMDA.
HC
Canada
Not listed by HC.
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Eyluxvi holds an approval, these are the other aflibercept biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| EMA | 8 | Alvotech (Afiveg / Mynzepli), Amgen (Pavblu), Biocon Biologics (Yesafili), Celltrion (Eydenzelt), Formycon (Ahzantive / Baiama), Sam Chun Dang Pharm (Eiyzey / Vgenfli), Samsung Bioepis (Opuviz), Sandoz (Enzeevu / Afqlir) |
Chronology
- EMASep 2025Authorised by the European Commission
Sources
S017EMA, medicines data table (medicines-output-medicines-report_en.xlsx) Primary (regulator)
Planning aflibercept biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.